Evidence map›Paper›PMID 35347489›Full record

ArticleClinical rheumatology2022

Autoantibody cluster analysis in juvenile lupus nephritis.

Matthew A Sherman, Amali Gunawardana, Janine P Amirault, Asha Moudgil, James E Bost, Sangeeta Sule, Hemalatha Srinivasalu

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical rheumatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Matthew A ShermanDivision of Rheumatology, Children's National Hospital, 111 Michigan Ave NW, Washington, DC, 20010, USA. msherman2@cnmc.org.ORCID http://orcid.org/0000-0002-5448-1538
Amali GunawardanaDepartment of Pediatrics, Johns Hopkins University, Baltimore, MD, USA.
Janine P AmiraultDepartment of Pediatrics, Boston Children's Hospital, Boston, MA, USA.
Asha MoudgilDivision of Nephrology, Children's National Hospital, Washington, DC, USA.
James E BostDivision of Biostatistics and Study Methodology, Children's National Research Institute, Children's National Hospital, Washington, DC, USA.
Sangeeta SuleDivision of Rheumatology, Children's National Hospital, 111 Michigan Ave NW, Washington, DC, 20010, USA.
Hemalatha SrinivasaluDivision of Rheumatology, Children's National Hospital, 111 Michigan Ave NW, Washington, DC, 20010, USA.
Children's National · USBoston Children's Hospital · USJohns Hopkins University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveDemographics, clinical features, and biomarkers do not consistently anticipate risk of end-stage renal disease (ESRD) in juvenile lupus nephritis (LN). Here, the existence of autoantibody clusters predictive of ESRD was explored in a cohort of biopsy-proven juvenile LN.

methodsA retrospective chart review was performed of patients with juvenile systemic lupus erythematosus (jSLE) and biopsy-confirmed LN. Primary endpoints were ESRD and mortality. Patients were included for K-medians cluster analysis if they had a complete autoantibody profile, which included ANA titer, anti-dsDNA, anti-Smith, anti-RNP, anti-Ro/SSA, anti-La/SSB. Chi-square test was used for categorical variables and one-way ANOVA for continuous measures. Significance was p<0.05.

resultsFifty-three met inclusion criteria, of which 45 were female and 37 were black. Over 80% developed LN within one year of jSLE onset and more than half (n=29) had LN at diagnosis of jSLE. Six developed ESRD. No mortalities were reported. Forty-six had a complete autoantibody profile, including four with ESRD. Three clusters were identified. Group 1 (n=8) was defined by anti-dsDNA; group 2 (n=28) by high-titer ANA (>1:1280), anti-Smith, anti-RNP, and anti-Ro/SSA; and group 3 (n=10) by anti-dsDNA and anti-Ro/SSA. There was no difference between the groups in demographics, jSLE manifestations, or markers of renal function. One in group 2 and three in group 3 developed ESRD. Those in group 3 were younger at diagnosis of LN (p=0.084) and had the highest frequency of ESRD (p=0.025).

conclusionCluster analysis revealed the highest frequency of ESRD in the group with LN defined by anti-Ro/SSA and anti-dsDNA co-positivity. Key Points • Lupus nephritis commonly is present at diagnosis of juvenile systemic lupus erythematosus or develops within the first year. • End-stage renal disease was more frequent in the cluster defined by anti-dsDNA and anti-Ro/SSA co-positivity; patients with this profile may benefit from more aggressive immunosuppression.

Indexed as

Kidney Failure, ChronicLupus Erythematosus, SystemicLupus NephritisAntibodies, AntinuclearAutoantibodiesBiomarkersCluster AnalysisDNAFemaleHumansMaleRetrospective StudiesAntibodies, AntinuclearAutoantibodiesBiomarkersDNAAnti-Ro/SSACluster analysisEnd-stage renal diseaseJuvenile systemic lupus erythematosusLupus nephritis

Identifiers

PMID35347489
OpenAlexW4221135369

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.